AB-001 is under clinical development by Agastiya Biotech and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-001 overview

AB-001 is under development for the treatment of biliary tract cancer, stomach cancer, colon cancer, breast cancer, carcinoid tumor, gallbladder cancer, liver cancer, pancreatic cancer, lung cancer, acute lymphocytic leukemia, glioblastoma, acute myeloid leukemia and coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is new chemical entity, administered through oral route. It acts by targeting PDL-1 and ACE-2.

Agastiya Biotech overview

Agastiya Biotech is a new medication development business focused on bringing to market unique pharmaceutical products. The company’s cutting-edge approaches have resulted in the development of various unique small compounds with patents for a variety of cancers, including the most difficult leukaemia and pancreatic cancer. The company is headquartered in United States.

For a complete picture of AB-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.